Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression: An observational study in patients with nonalcoholic fatty liver disease

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Pelusi, Serena ^a   Petta, Salvatore ^b   Rosso, Chiara ^c   Borroni, Vittorio ^a   Fracanzani, Anna Ludovica ^a   Dongiovanni, Paola ^a   Craxi, Antonio ^b   Bugianesi, Elisabetta ^c   Fargion, Silvia ^a   Valenti, Luca ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

ADULT; APRI SCORE; ARTICLE; COHORT ANALYSIS; DIGESTIVE SYSTEM DISEASE ASSESSMENT; FEMALE; FIBROSIS PROGRESSION RATE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPERTENSION; ITALIAN (CITIZEN); LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; TERTIARY CARE CENTER; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; DRUG EFFECTS; ITALY; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; LIVER; LIVER CIRRHOSIS; MALE; METFORMIN; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84991740043     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0163069     Document Type: Article

References (37)

1. Petta S, Valenti L, Bugianesi E, Targher G, Bellentani S, Bonino F. A "systems medicine" approach to the study of non-alcoholic fatty liver disease. Dig Liver Dis 2016; 48(3):333-42. doi: 10.1016/j.dld.2015. 10.027 PMID: 26698409
2. Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V et al. Statin use and nonalcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63:705-12. doi: 10.1016/j.jhep.2015.05.006 PMID: 25980762
3. Dongiovanni P, Rametta R, Meroni M, Valenti L. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development-a potential therapeutic target? Expert Rev Gastroenterol Hepatol 2015:1-14.
4. Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism 2015.
5. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50(8):1844-50. PMID: 11473047
6. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015; 149(2):389-97 e10. doi: 10.1053/j.gastro. 2015.04.043 PMID: 25935633
7. Ekstedt M, Hagstrom H, Nasr P, Fredikson M, Stål P, Kechagias S et al. Fibrosis stage is the strongest predictor for disease-specific mortalityin NAFLD after up to 33 years of follow-up. Hepatology 2015; 61 (5):1547-54. doi: 10.1002/hep.27368 PMID: 25125077
8. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitisusing paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62(5):1148-55. doi: 10.1016/j.jhep.2014.11.034 PMID: 25477264
9. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13(4):643-54.e1-9; quiz e39-40. doi: 10.1016/j.cgh.2014.04.014 PMID: 24768810
10. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44(4):865-73. PMID: 17006923
11. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013; 59 (3):550-6. doi: 10.1016/j.jhep.2013.04.027 PMID: 23665288
12. Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for non-alcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology 2015.
13. Matthew Morris E, Fletcher JA, Thyfault JP, Rector RS. The role of angiotensin II in nonalcoholic steatohepatitis. Mol Cell Endocrinol 2013; 378(1-2):29-40. doi: 10.1016/j.mce.2012.04.013 PMID: 22579612
14. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121 (1):148-55. PMID: 11438504
15. Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005; 41(5):1046-55. PMID: 15841463
16. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 45(6):1375-81. PMID: 17518368
17. Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, Swart J et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010; 51(3):942-52. doi: 10.1002/hep.23419 PMID: 20044807
18. Yang L, Bataller R, Dulyx J, Coffman TM, Ginès P, Rippe RA et al. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005; 43(2):317-23. PMID: 15964094
19. Sturzeneker MC, Ioshii SO, Villela Baroncini LA, Precoma DB. Olmesartanseverely weakened the development of NASH in an animal model of hypercholesterolemia. Atherosclerosis 2011; 216(1):97-102. doi: 10.1016/j.atherosclerosis.2011.01.047 PMID: 21338989
20. Wu Y, Ma KL, Zhang Y, Wen Y, Wang GH, Hu ZB et al. Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contributes to non-alcoholic fatty liver disease. Liver Int 2016.
21. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40 (5):1222-5. PMID: 15382153
22. Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology 2011; 54(5):1631-9. doi: 10.1002/hep.24558 PMID: 21748770
23. Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int 2015; 35(3):979-85. doi: 10.1111/liv. 12611 PMID: 24905085
24. Orlic L, Mikolasevic I, Lukenda V, Anic K, Jelic I, Racki S. Nonalcoholic fatty liver disease and the reninangiotensin system blockers in the patients with chronic kidney disease. Wien Klin Wochenschr 2015; 127(9-10):355-62. doi: 10.1007/s00508-014-0661-y PMID: 25412597
25. Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015; 61(2):506-14. doi: 10.1002/hep.27490 PMID: 25251399
26. Valenti L, Fracanzani AL, Dongiovanni P, Rovida S, Rametta R, Fatta E et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014; 20(11):3002-10. doi: 10.3748/wjg.v20.i11.3002 PMID: 24659891
27. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39(2):239-44. PMID: 12873821
28. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41(6):1313-21. PMID: 15915461
29. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016.
30. Petta S, Valenti L, Marra F, Grimaudo S, Tripodo C, Bugianesi E et al. MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. J Hepatol 2016; 64(3):682-90. doi: 10.1016/j.jhep.2015.10.016 PMID: 26596542
31. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37(4):917-23. PMID: 12668987
32. Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology 2016; 63(1):107-16. doi: 10.1002/hep.28287 PMID: 26473614
33. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48(3):792-8. doi: 10.1002/hep.22429 PMID: 18752331
34. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008; 4(1):39-45. PMID: 18220694
35. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015; 116(6):991-1006. doi: 10.1161/CIRCRESAHA.116. 305697 PMID: 25767285
36. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47(1):135-41. PMID: 17400325
37. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011; 55(4):920-32. doi: 10.1016/j.jhep.2011.05.008 PMID: 21718726